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Edited by Thomas L. JamesAbstract Multiple sclerosis is a major cause of non-traumatic
neurological disability. The identiﬁcation of markers that
diﬀerentiate disease progression is critical to eﬀective therapy.
A combination of NMR spectroscopic metabolic proﬁling of
urine and statistical pattern recognition was used to detect focal
inﬂammatory central nervous system (CNS) lesions induced by
microinjection of a replication-deﬁcient recombinant adenovirus
expressing TNF-a or IL1-b cDNA into the brains of Wistar rats.
These animals were compared with a group of na€ıve rats and a
group of animals injected with an equivalent null adenovirus.
Urine samples were collected 7 days after adenovirus injection,
when the inﬂammatory lesion is maximally active. Principal
components analysis and Partial Least Squares-Discriminate
analysis of the urine 1H NMR spectra revealed signiﬁcant
diﬀerences between each of the cytokine adenovirus groups and
the control groups; for the TNF-a group the main diﬀerences lay
in citrate and succinate, while for the IL-1b group the predom-
inant changes occurred in leucine, isoleucine, valine and myo-
inositol. Thus, we can identify urinary metabolic vectors that not
only separate rats with inﬂammatory lesions in the brain from
control animals, but also distinguish between diﬀerent types of
CNS inﬂammatory lesions.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Multiple sclerosis (MS) is an immune-mediated disease of
the central nervous system (CNS), characterised by demye-
lination, axonal loss, T cell and macrophage recruitment, and
blood–brain barrier breakdown [1]. Lesions are often clinically
silent and only detectable by cranial MRI. Anti-inﬂammato-
ries have been shown to reduce periods of relapse and lesion
spread during relapsing-remitting MS, while steroids are be-
lieved to slow the onset of secondary-progressive MS [2].
However, a continuous suppression of the immune system is
undesirable. Consequently, it is of importance to identify easily* Corresponding author. Fax: 44-0-1223-760002.
E-mail address: jlg40@mole.bio.cam.ac.uk (J.L. Griﬃn).
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doi:10.1016/j.febslet.2004.04.096accessible biological markers that enable reliable diﬀerentia-
tion of the diﬀerent phases of the disease.
Monitoring disease progression using body ﬂuids has been
applied previously to both MS patients and animal models
[3,4], but these studies examined predetermined metabolites
and had mixed success. High resolution 1H NMR spectro-
scopic analysis of bioﬂuids, and in particular urine and blood
plasma, has become increasingly more common in the phar-
maceutical industry’s drug safety assessment process as a
method for identifying target organ toxicity through urinary
biomarkers [5,6]. Such metabonomic/metabolomic analysis has
also recently been extended to predicting the presence and
severity of coronary artery disease in humans [7]. This ap-
proach of bioﬂuid metabolic proﬁling and statistical pattern
recognition requires no a priori knowledge, identifying me-
tabolites solely according to their correlated variation between
treatment groups [8]. Furthermore, multivariate pattern rec-
ognition techniques such as principal components analysis
(PCA) can identify distinct patterns of metabolites whose
variation as a whole is characteristic of the disease, rather than
rely on the identiﬁcation of a unique biomarker of the disease
[8].
Using such an approach ‘t Hart et al. [9] identiﬁed charac-
teristic biochemical patterns in the urines of MS patients and
in marmosets following experimental autoimmune encephal-
opathy (EAE). This study found that there were a number of
changes in the composition of organic chemicals in the urine of
marmosets following EAE, with the region between 0.5 and 3.5
ppm being important in distinguishing this group from con-
trols. However, there are a number of metabolites found in this
spectral region, and thus, the model did not provide an insight
into the mechanisms being monitored. Furthermore, the EAE
model produces large lesions, unlike the more focal lesions
usually found in MS. However, their approach was also able to
build a pattern recognition model that was 65% accurate in
distinguishing urine from MS patients compared with healthy
individuals and patients suﬀering from other neurological
disorders, suggesting that bioﬂuid NMR could be used to
monitor MS.
The principal mediators of inﬂammatory responses in the
body are the cytokines, a family of small, soluble proteins
which modulate the immune system. Two key proinﬂamma-
tory cytokines are interleukin-1b (IL-1b) and tumour necrosisblished by Elsevier B.V. All rights reserved.
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found to be associated with a broad spectrum of CNS injury
and disease, including MS [10,11]. The aim of this study was to
determine whether a combination of NMR spectroscopic
metabolic proﬁling of urine samples and statistical pattern
recognition could detect the presence of IL-1b and TNF-a
induced CNS lesions and distinguish between the distinct
neuropathologies caused. We have identiﬁed urinary metabolic
perturbations that separate rats with inﬂammatory CNS le-
sions from control animals and which distinguish between two
diﬀerent types of inﬂammatory lesion in the brain. These
ﬁndings suggest that this approach may be useful for following
the progression and treatment of MS in humans in the early
stages of the disease by monitoring the metabolic signatures
associated with a particular cytokine response.2. Materials and methods
2.1. Animal procedures
A focal inﬂammatory lesion in the left striatum of adult male Wistar
rats was induced by microinjection of a replication-deﬁcient re-
combinant adenoviral vector [12,13]: (i) adenovirus expressing murine
membrane-bound TNF-a cDNA (Ad5TNF-am) (n ¼ 7); (ii) adenovi-
rus expressing murine IL-1b cDNA (Ad5IL-1b) (n ¼ 7); and (iii) an
adenovirus with no insert in the E1 region (AdDL70) (a control group
where no cytokine is induced; n ¼ 5). Animals were anaesthetised with
2.5% isoﬂurane in 70% N2O:30% O2 and injected stereotaxically over a
10-minute period (Bregma +1 mm, 3 mm lateral, depth 4 mm) with 107
PFU of adenovirus in 1 ll of saline using a <50 lm-tipped glass pi-
pette. Urine samples were collected from animals 7 days after adeno-
virus injection, at which time previous immunocytochemical analysis
demonstrated activation of resident microglia, and maximal leukocyte
recruitment to the brain [12,13]. At seven days the histological features
of the lesions induced by IL-1b and TNF-a are well characterised and
distinct, but at earlier time points the lesions are less speciﬁc in terms of
the leukocyte recruitment proﬁle. Urine samples were also acquired
from non-injected control animals (n ¼ 2) for comparison. Urine
samples were collected from each individual animal by gently de-
pressing the abdomen of the animals to encourage them to urinate.
This procedure avoided faecal contamination of the urine. Urine was
frozen and stored at )80 C until examined by NMR spectroscopy. All
procedures were approved by the United Kingdom Home Oﬃce.
2.2. Histological analysis
Following urine collection, animals were deeply anaesthetised with
sodium pentobarbitone and transcardially perfused with 200 ml of
0.9% heparinised saline followed by 200 ml periodate lysine parafor-
maldehyde. After dissection, the brains were post-ﬁxed for several
hours in the ﬁxative and then immersed in 30% sucrose buﬀer for 24 h
to cryoprotect. The tissue was then embedded in Tissue Tek (Miles Inc,
Elkhart, USA) and frozen in isopentane at )40 C. Cresyl violet-
stained sections (50 lm) were examined for signs of neuronal damage
and for the presence of leukocytes. Immunohistochemistry was used to
conﬁrm the presence and distribution of speciﬁc cell populations.
Frozen, 10 lm thick, serial sections were cut from the ﬁxed tissue and
mounted on gelatin-coated glass slides. Antigens were detected using a
three-step indirect method [14]. Polymorphonuclear neutrophils were
identiﬁed using the anti-neutrophil serum HB199 [15] and macro-
phages were identiﬁed using the monoclonal antibodies ED1 [16],
which stains most macrophage populations including recruited
monocytes, but not quiescent microglia. T and B cells were identiﬁed
using an in-house mouse monoclonal antibody, OX42 (available on
request from D.C.A.). Neurones were identiﬁed using anti-NeuN
monoclonal antibody (Chemicon International) and 25-lm-thick fro-
zen sections were processed for cholinesterase histochemistry using
acetylthiocholine as substrate.
2.3. NMR spectroscopy
Urine (300 ll) was diluted in a buﬀered phosphate solution (210 ll of
0.2 M Na2HPO4/ 0.04 M NaH2PO4, pH 7.4, 0.1% sodium azide) and90 lL of TSP (3-trimethylsilyl-1-[2,2,3,3,-2H4] propionate; 1 mM ﬁnal
concentration; internal standard) both in deuterium oxide. NMR
spectra of urine were acquired at 600 MHz 1H NMR frequency using a
standard solvent suppression pulse sequence (NOESYPR1D, mixing
time¼ 50 ms, relaxation delay¼ 1.75 s) and a Bruker AVANCE
spectrometer (Bruker Gmbh, Germany). Spectra were subdivided into
0.04 ppm integral regions and integrated, reducing each spectrum to
200 independent variables between 0.5–4.28 and 6.04–9.96 ppm and
forming the matrix for pattern recognition [17]. The region between
4.28 and 6.04 ppm was excluded to avoid the region of water sup-
pression and the broad resonance from urea, both of which represents
highly variable regions in the spectra. PCA and Partial Least Squares-
Discriminate analysis (PLS-DA) were applied within the software
package SIMCA 9.0 (Umetrics, Umea, Sweden). Prior to pattern
recognition, the spectra (observables) were scaled using a Pareto
scaling, where each integral region was centred about the mean and
divided by the square route of the standard deviation of the mean [18].
PLS-DA is a supervised regression extension of PCA, where the al-
gorithm is instructed of class membership and maximises the separa-
tion in multivariate space according to these classes. To test this
supervised pattern recognition, the class membership of each spectrum
was predicted by omitting each spectrum in turn from a PLS-DA
model of the other spectra and predicting its class membership.
To conﬁrm the assignments made from the one-dimensional 1H
NMR spectra, a urine sample from each treatment group was also
examined using a gradient Correlation Spectroscopy (COSY) pulse
sequence with solvent suppression. The COSYs were acquired with a
1.5 s relaxation delay, a sweep width of 8503 Hz, 16 acquisitions and
256 increments in the F1 dimension.3. Results
3.1. Inﬂammatory lesions
The adenovirus injections caused focal over-expression of
either membrane-bound TNF-a or IL1-b leading to the de-
velopment of a focal inﬂammatory lesion in the left striatum
(Fig. 1) that persisted for the seven day period. Injection of
Ad5TNF-am gave rise to marked macrophage and T-cell re-
cruitment to the brain (Fig. 1(a)), followed by demyelination
and neuronal loss without overt clinical signs. In contrast,
injection of Ad5IL-1b gave rise to marked neutrophil recruit-
ment to the brain (Fig. 1(b)), again followed by demyelination,
but without any overt neuronal cell death. Injection of the null
adenovirus (AdDL70) yielded no histopathological signs of
inﬂammation or injury that were visible after 7 days (data not
shown). TNF-a, IL-1b and IL-6 were not detected by ELISA
in the serum of any animal, indicating that the expression of
cytokines was restricted to the CNS and that they did not leak
in any measurable amount into the circulation (data not
shown). No weight changes were detected in any of the animals
during the study.3.2. Urine analysis
High resolution 1H NMR spectroscopy produced spectra of
the urine samples that readily identiﬁed and quantiﬁed over 30
metabolites. The urinary metabolites were identiﬁed by refer-
ence to previous literature values [19] and the use of COSY
spectra (Fig. 2). However, while the spectra were superﬁcially
similar, the proportion of these metabolites appeared to be
characteristic of the insult induced (Fig. 3). The urine from rats
treated with Ad5TNF-am produced spectra that were domi-
nated by citrate, 2-oxoglutarate and creatine compared with
the control group. On the other hand, the urine of rats exposed
to Ad5IL-1b had increased concentrations of leucine, isoleu-
cine, valine, isobutyrate, N-acetyl glycoproteins and acetate
compared with the other two groups. To place the visual
Fig. 1. (a) Immunolocalisation of activated microglia and recruited
macrophages (brown stained OX42-positive cells) delineating the
lesion on a horizontal section one week after an injection of 107 pfu
replication-deﬁcient recombinant adenovirus expressing murine TNF-
a cDNA. (b) Immunolocalisation of recruited neutrophils (identiﬁed
by the nuclear morphology) delineating the lesion on a coronal section
one week after an injection of 107 pfu replication-deﬁcient re-
combinant adenovirus expressing murine IL-1b cDNA. In both cases,
cresyl violet was used to counter-stain the nuclei. Scale bar¼ 1 mm.
Fig. 2. 600.13 MHz COSY spectrum of rat urine from a rat exposed to
Ad5IL-1b used to conﬁrm assignments of coupled resonances. Key: 1,
n-butyrate; 2, n-butyrate; 3, valine; 4, leucine; 5, lactate; 6, 2-oxoglu-
tarate; 7, aspartate; 8, citrate; 9, lysine; 10, glucose containing region.
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ognition was applied.
Applying PCA to the data set of urine spectra, separation of
the proﬁles from treated rats was across PC1 and PC2, with thetwo treated groups showing distinct perturbations from the
combined control data set across either PC1 (Ad5IL-1b treated
group) or PC2 (Ad5TNF-am treated group) (Fig. 4(a)). The
combined PCs represented 58% of the variation in the data set.
Examining the loadings that contributed to the separation of
Ad5IL-1b treated rats from control animals, this was caused
by increases in leucine, isoleucine, and valine (d 0.96, 1.16,
1.12; where d is the chemical shift of the centre of the 0.04 ppm
region identiﬁed by the pattern recognition), isobutyrate (d
1.12, 1.16), ethanol ( 1.16; a contaminant) and glucose (d 3.44,
3.58, 3.88). This separation was still apparent when the reso-
nance region corresponding to ethanol was removed from the
model. Ad5TNF-am treated animals had increased excretion of
citrate (d 2.68, 2.54) and 2-oxoglutarate (d 2.44, 3.00)
(Fig. 4(b)). During this analysis the rats receiving no treatment
(naives) and the sham controls (receiving a null adenovirus)
mapped to the same PC location, and hence were treated as a
single control group.
Repeating this analysis using PLS-DA, to produce orthog-
onal vectors that maximise the diﬀerence between groups, the
separation between groups was also apparent. PLS-DA pro-
duced a four component model that separated all three groups
across PLS-DA components 1 and 2 (Fig. 4(c)). For the
Ad5IL-1b treated group, separation from the control group
was caused by increases in leucine, isoleucine and valine
(d 0.96, 1.12), isobutyrate (d 1.16) glucose (d 3.44, 3.56, 3.88),
creatine (d 3.04, 3.96) and trimethylamine oxide (TMAO)
(d 3.24). Again Ad5TNF-am treated animals demonstrated
increased excretion of citrate and 2-oxoglutarate (Fig. 4(d)).
As the separation in the PLS-DA model was caused by a
number of high concentration metabolites which would have
signiﬁcant leverage over the model, to identify other potential
biomarkers of eﬀect, the above metabolites were excluded and
a new PLS-DA model produced. Again the urine from animals
exposed to Ad5IL-1b and Ad5TNF-am were separated from
the combined control group. Animals exposed to Ad5IL-1b
had increased concentrations of cysteine (d 3.08, 3.12), taurine
(d 3.40) and acetate (d 1.96), while animals exposed to
Ad5TNF-am had increased concentrations of succinate
(d 2.40), hippurate (d 7.84, 7.64, 7.52) and phenylacetylglycine
(d 7.36, 3.76, 3.68). Subsequent exclusion of these metabolites
in addition to those mentioned above caused the PLS-DA
model to fail in distinguishing the three groups.
Rebuilding PLS-DA models but sequentially excluding from
the model training process one spectrum and subsequently
predicting the class membership of the animal using the built
model allowed us to estimate the predictive ability of our ap-
proach. Of a total of 19 animals, 15 were correctly classiﬁed
into the right treatment group using this process. Thus, the
model’s predictive power of 79% was far greater than that
produced by chance (33%).
As the multivariate analysis demonstrated that the two
exposure groups separated in opposite directions from the
control group, the data were also processed as a two-way
comparison (models not shown). The animals exposed to
Ad5IL-1b had an increased concentration of taurine (d 3.28,
3.40) and decreased concentrations of hippurate (d 7.84, 7.52),
succinate (d 2.40) and citrate (d 2.72) compared with the
combined control group. The animals exposed to Ad5TNF-am
had increased concentrations of glucose (d 3.72, 3.64, 3.60) and
phenylacetylglycine (d 7.36, 3.76, 3.68). Finally, the two
exposure groups could be separated with animals exposed to
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(d 3.28, 3.40) and decreased concentrations of citrate (d 2.72),
succinate (d 2.40) and hippurate (d 7.84, 7.52) compared with
animals exposed to Ad5TNF-am.4. Discussion
In this study, we have identiﬁed urinary metabolic vectors
that separate rats with inﬂammatory CNS lesions from control
animals. Furthermore, these vectors distinguish between two
diﬀerent types of inﬂammatory lesion in the brain. These
ﬁndings suggest that the combination of NMR spectroscopic
urinary proﬁling and statistical pattern recognition may be a
useful approach for following disease progression and treat-
ment in individuals with inﬂammatory lesions in the brain,
such as MS patients.
MS is associated with chronic expression of the key proin-
ﬂammatory cytokines, TNF-a and IL1-b [20]. In this study, we
have used an adenoviral vector to induce chronic endogenous
expression of either IL-1b or TNF-a in the rat brain. We have
previously demonstrated that, in contrast to their eﬀects in the
periphery, these cytokines give rise to markedly diﬀerent in-
ﬂammatory proﬁles within the CNS following single bolus
microinjection into the brain parenchyma [13,21–23]. Simi-
larly, in the current study expression of IL-1b led to predom-
inantly polymorphonuclear leukocyte-mediated inﬂammatory
response, whilst TNF-a gave rise to a predominantly mono-
cyte-mediated lesion. Signiﬁcant diﬀerences were found be-
tween these groups in terms of their urinary analysis,
suggesting that the diﬀerent types of inﬂammatory lesions have
distinctly diﬀerent consequences in the periphery.
Speciﬁcally, the Ad5IL-1b treated group predominantly ex-
hibited increases in leucine, isoleucine, valine, n-butyrate and
glucose, whilst the Ad5TNF-am treated animals demonstrated
increased excretion of citrate, 2-oxoglutarate and succinate.
Given the focal nature of the lesions induced in this study,
metabolite changes detected in urine are likely to be a sec-
ondary eﬀect of the lesion. Indeed, it is known that following
infection or injury to the CNS, the liver releases acute phase
proteins [24]. A signiﬁcant component of the hepatic acute
phase response is the release of chemokines by the liver, which
control and amplify the CNS response to injury by controlling
the rate, timing, magnitude and composition of leukocyte re-
cruitment to the damaged brain and to the liver. We have
found that enzyme markers of liver tissue injury are increased
in the serum following generation of a focal inﬂammatory le-
sion in the brain [24–26]. Thus, the diﬀerent urinary biomar-
kers may reﬂect the diﬀerent responses in the liver to Ad5IL-1b
and Ad5TNF-am.
However, increased excretion of the organic acids citrate,
succinate and 2-oxoglutarate are commonly seen in drug tox-
icity studies in rats [25–28]. This suggests that the major bio-
markers associated with exposure to Ad5TNF-am reﬂect a
general metabolic perturbation related to stress. However, if
similar metabolic responses are detectable in MS patients,
these general metabolic markers of stress could still be used as
surrogate markers for relapse. Furthermore, these metabolites
represent those most responsible for the classiﬁcation and will
not represent all the metabolites perturbed in the urine sample.
We were able to identify and quantify 30 metabolites in this
study, but this excluded many smaller resonances. These mayeither provide unique biomarkers for Ad5TNF-am and Ad5IL-
1b lesions, or alternatively, the proportion of metabolites
could be used to reconstruct metabolic correlation maps, akin
to those constructed for yeast and plants [29], which might
suggest which pathways are perturbed.
While the intermediate steps to the urine proﬁles are unclear,
it remains the case that we were able to distinguish between
distinct pathologies with the brain and raises the possibility
that the pathogenesis of inﬂammatory lesions and total lesion
load might be followed by applying metabolomics/metabo-
nomics to urine analysis. These experiments were performed
on a laboratory strain of rat, fed on a controlled diet, and
applying such an approach directly to humans will be con-
founded by greater physiological and dietary variation. How-
ever, urine samples can be monitored across time on an
individual basis, to identify when that individual enters a
relapse. Indeed, such temporal studies are particularly ame-
nable to batch processing pattern recognition techniques that
use a time component to identify outliers [30] (i.e., the relapse
episode). Furthermore, systemic biomarkers may also be ap-
parent in blood plasma, with as little as 2-5 ll of plasma being
required for such analysis [31]. Indeed, metabolic proﬁling has
already been demonstrated to be eﬀective at distinguishing
severity in coronary artery disease [7] and high blood pressure
[32] through biomarkers detected in blood plasma. However,
urine has a number of distinct advantages over examining
blood plasma directly. Blood plasma contains lipoproteins and
lipids which can obscure a signiﬁcant amount of the spectral
sweep width. It is relatively closely controlled in terms of
composition, and would be expected to be perturbed less than
urine, where metabolites can be concentrated signiﬁcantly.
Also the metabolic proﬁles of blood plasma provide a snap-
shot of metabolism, rather than an average of the metabolic
changes over a period of time. Thus, if we had used blood
plasma we might have missed key metabolic changes. In con-
clusion, this study demonstrates that the use of metabolic
proﬁling by NMR spectroscopy for the treatment of MS is
now a realistic possibility.
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